<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20030630084905</creation_date><modification_date>D:20030630084908+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-168_h_w_dec_5.pdf</pdf_file></head><body><section><header>i</header></section><section><header>en</header><p>commission of the european communitiesbrussels, 25/06/2003c(2003) 2086
 not for publication</p></section><section><header>commission decisionof 25/06/2003
 amending decision c(2001)286 on the marketing authorization for
 the medicinal product for human use
 &quot;tenecteplase boehringer ingelheim pharma gmbh &amp; co. kg - tenecteplase&quot;
  (text with eea relevance)</header><p>only the german text is authentic.ii</p></section><section><header>commission decisionof 25/06/2003
 amending decision c(2001)286 on the marketing authorization for
 the medicinal product for human use
 &quot; tenecteplase boehringer ingelheim pharma gmbh &amp; co. kg - tenecteplase&quot;
  (text with eea relevance)</header><p>the commission of the european communities,having regard to the treaty establishing the european community,
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down
 community procedures for the authorisation and supervision of medicinal products for
 human and veterinary use and establishing a european agency for the evaluation of
 medicinal products
 1, as amended by commission regulation (ec) no 649/982,having regard to commission regulation (ec) no 542/95 of 10 march 1995 concerning
 the examination of variations to the terms of a marketing authorisation falling within the
 scope of council regulation (eec) no 2309/93
 3, as amended by commissionregulation (ec) no 1069/98
 4, and in particular article 5(2) thereof,having regard to the opinion of the european agency for the evaluation of medicinal
 products,
 whereas:
 (1)</p><p>the medicinal product &quot; tenecteplase boehringer ingelheim pharma gmbh &amp;
 co. kg - tenecteplase&quot; entered in the community register of medicinal products
 under 
 nos 
 eu/1/00/168/001-006 
 authorised 
 by 
 commission 
 decision
 c(2001)286 of 23 february 2001, as amended, complies with the requirements set
 out in regulation (eec) no 2309/93.
 (2)</p><p>boehringer ingelheim international gmbh submitted an application on 5 may
 2003 pursuant to article 4(1) set out in regulation (ec) no 542/95.
 (3)</p><p>the european agency for the evaluation of medicinal products delivered a
 favourable opinion formulated on 21 may 2003 by the committee for proprietary
 medicinal products,</p><p> 
 1 oj no l 214, 24. 8. 1993, p. 1.2 oj no l 88, 24. 3. 1998, p. 7.3 oj no l 55, 11.3.1995, p. 154 oj l 153, 27.5.1998, p. 11iii(4)</p><p>decision c(2001)286 should therefore be amended accordingly.
 (5)</p><p>in accordance with article 5(2) of regulation (ec) no 542/95, this decision shall
 take effect retroactively on the 31st day following receipt by the european
 agency for the evaluation of medicinal products of the application relating to it.
 has adopted this decision:
 article 1decision c(2001)286 is amended as follows:1. annex i is replaced by annex i to this decision;
 2. annex ii is replaced by annex ii to this decision;
 3. annex iii (a and b) is replaced by annex iii to this decision.
 article 2this decision shall apply from 4 june 2003.article 3this decision is addressed to boehringer ingelheim international gmbh, binger strasse173, d-55216 ingelheim am rhein, deutschland.
 done at brussels, 25/06/2003
 for the commissionerkki liikanen
 member of the commission</p></section></body></xml>